NEW YORK (GenomeWeb News) – Bruker today provided updated financial guidance for fiscal year 2009, saying in a presentation at the Thomas Weisel Partners Healthcare Conference in Boston that it expects a year-over-year revenue decline of approximately 2 percent.
The firm had previously said that it expected flat to a low single-digit decline in revenues for the year.
Bruker also said that it is not likely to meet its previous goal of improving upon its 2008 earnings per share of $.45.
However, Bruker said that global stimulus programs could contribute 5 percent — roughly $50 million — or greater revenue growth its core scientific business instruments business in 2010.
Two weeks ago, the firm had revealed in a filing with the US Securities and Exchange Commission that it had taken in $10 million in orders due to stimulus programs in the US, Japan, and Europe.
In early trade on the Nasdaq, shares of Bruker were up 2 percent at $11.